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Inﬂuenza A virus is being extensively studied because of its major
impact on human and animal health. However, the dynamics of
inﬂuenza virus infection and the cell types infected in vivo are
poorly understood. These characteristics are challenging to deter-
mine, partly because there is no efﬁcient replication-competent
virus expressing an easily traceable reporter gene. Here, we report
the generation of a recombinant inﬂuenza virus carrying a GFP
reporter gene in the NS segment (NS1-GFP virus). Although atten-
uated when compared with wild-type virus, the NS1-GFP virus
replicates efﬁciently in murine lungs and shows pathogenicity in
mice. Using whole-organ imaging and ﬂow cytometry, we have
tracked the dynamics of inﬂuenza virus infection progression in
mice. Imaging of murine lungs shows that infection starts in the
respiratory tract in areas close to large conducting airways and
later spreads to deeper sections of the lungs. In addition to epi-
thelial cells, we found GFP-positive antigen-presenting cells, such
as CD11b+CD11c−, CD11b−CD11c+, and CD11b+CD11c+, as early as
24 h after intranasal infection. In addition, a signiﬁcant propor-
tion of NK and B cells were GFP positive, suggesting active infec-
tion of these cells. We next tested the effects of the inﬂuenza virus
inhibitors oseltamivir and amantadine on the kinetics of in vivo
infection progression. Treatment with oseltamivir dramatically re-
duced inﬂuenza infection in all cell types, whereas, surprisingly,
amantadine treatment more efﬁciently blocked infection in B and
NK cells. Our results demonstrate high levels of immune cells har-
boring inﬂuenza virus antigen during viral infection and cell-type–
speciﬁc effects upon treatment with antiviral agents, opening addi-
tional avenues of research in the inﬂuenza virus ﬁeld.
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Inﬂuenza A virus (IAV), a member of the Orthomyxoviridaefamily, causes respiratory disease that can be very severe, es-
pecially in very young children and elderly individuals (1). Apart
from yearly seasonal outbreaks, IAV can cause frequent epide-
mics and occasional pandemics in humans (2, 3). Vaccination has
been one of the most effective means of protection against in-
ﬂuenza virus infection. In addition, there are two categories of
Food and Drug Administration-approved drugs used for treat-
ment of IAV infections: (i) M2 inhibitors, which block viral un-
coating and entry (amantadine and rimantadine); and (ii) NA
inhibitors, which block viral spreading (oseltamivir and zanami-
vir; reviewed in refs. 4–7).
Although studies on IAV using animal models and tissue cul-
ture have provided tremendous knowledge about both the viral
and host factors that determine pathogenesis, following viral in-
fection in vivo may provide us with a more complete picture of
the complex interactions between the virus and the host (8). Such
in vivo studies have been hampered primarily due to the lack of
fully virulent IAV-expressing reporter genes that can be easily de-
tected in vivo. Previous studies have attempted to create repli-
cation competent IAV viruses carrying a GFP reporter gene by
replacing portions of the NS1 or the NA segments with GFP (9,
10). However, most of these viruses have reduced levels of rep-
lication and do not show signiﬁcant pathogenesis in mice (9).
Therefore, a number of basic questions related to IAV infection
progression in vivo, and the extent to which different cell types are
infected by the virus in the respiratory tract, remain unanswered.
In this study, using reverse genetics, we have generated a recom-
binant IAV carrying a GFP reporter in the NS segment (NS1-GFP
virus). This work describes the successful generation of a mouse-
lethal IAV virus expressing a ﬂuorescent protein. Despite some
levels of attenuation, the NS1-GFP virus replicates efﬁciently in
eggs, Madin–Darby canine kidney (MDCK) cells, and in murine
lungs. We characterized the in vivo dynamics of IAV infection
progression in mice and identiﬁed different cell types that are sus-
ceptible to inﬂuenza virus infection. Whole-organ imaging of NS1-
GFP virus–infected lungs was consistent with IAV infections
starting in the respiratory tract near the trachea and main stem
bronchi, spreading with time into bronchioles. Also, we have tested
twowell-known antiviral agents, amantadine and oseltamivir, which
block virus uncoating and virus spreading, respectively. By visual-
izing the in vivo targets of IAV infection and the dynamics of in-
fection progression, we are likely to gain a better understanding of
IAV pathogenesis. In addition, a replication-competent IAV
expressing GFP can serve as an important tool to more precisely
analyze the impact in vivo of different vaccine strategies, immune
modulators, and antiviral agents against IAV.
Results
Generation of IAV Expressing GFP. The NS segment of IAV encodes
two proteins: NS1 produced from unspliced mRNA, and NEP
produced from spliced mRNA (Fig. 1A). It has been previously
shown that functionally active NS1 and NEP can be expressed as
a single polyprotein with a foot and mouth disease virus (FMDV)
2A autoproteolytic cleavage site (11). During translation, the NS1
protein is separated from NEP by the cleavage of site 2A. In this
study, we modiﬁed the NS segment to express NS1-GFP and NEP
as a single polyprotein with a 19aa porcine teschovirus–1 (PTV-1)
2A autoproteolytic cleavage site between them, allowing NEP to
be released from the upstream NS1-GFP protein during trans-
lation (11, 12). Also, we introduced two silent mutations in the
splice acceptor site to prevent splicing of NS mRNA (11). The
NS1-GFP virus was rescued using standard reverse genetics
techniques as previously described (13). Although the initial res-
cue supernatant contained a mixture of both GFP-positive and
GFP-negative virus populations, we were able to isolate a stable
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GFP carrying clone after three rounds of plaque puriﬁcation. To
test whether GFP was expressed in all infected cells, A549 cells
were infected with the NS1-GFP virus at a MOI of 1 and stained
for the viral nucleoprotein (NP), a viral protein critical for repli-
cation (Fig. 1B). At 10 h postinfection (hpi), NS1-GFP expression
was observed in all cells expressing NP (infected cells), demon-
strating that GFP is expressed in all infected cells (Fig. 1B). In
addition, NS1-GFP virus was capable of undergoing multiple
rounds of replication, formed visible GFP-expressing plaques
(Fig. 1C), and grew to titers of 5 × 108 pfu/mL in 9-d-old em-
bryonated eggs. The quality of the NS1-GFP virus preparation
was further determined by examining GFP expression in 20 ran-
domly selected visible plaques. Only preparations in which all 20
plaques were GFP positive were used in our experiments.
In Vitro Characterization of NS1-GFP Virus. NS1-GFP virus replicates in
MDCK cells. To test whether the presence of a longer NS segment
in NS1-GFP virus, which is approximately twice the size of the
wild-type PR8 (WT PR8) NS segment (1.89 kb vs. 0.89 kb),
affects the virus replication cycle in tissue culture, we compared
the growth kinetics of NS1-GFP virus and parental virus WT
PR8 in MDCK cells (Fig. S1A). MDCK cells were infected with
either NS1-GFP or WT PR8 virus at MOI of 1 or of 0.001, and at
various time points postinfection the viral titers in the superna-
tant were quantiﬁed by plaque assay. In a single-cycle replication
assay (MOI = 1), NS1-GFP virus showed growth patterns simi-
lar to those of WT PR8 virus, with titers reaching up to 2 × 107
pfu/mL However, in a multicycle replication assay (MOI =
0.001), NS1-GFP virus showed a slight delay in replication ki-
netics, with titers reaching up to 4 × 105 pfu/mL. This indicates
that NS1-GFP virus can undergo multicycle replication in MDCK
cells, albeit reaching ≈100-fold lower titers than WT virus.
Next, the NS1 protein expression proﬁle was examined in in-
fected MDCK cells by Western blot analysis (Fig. S1B). In the
WT PR8-infected cells, NS1 expression can be seen as early as
6 hpi. In NS1-GFP virus–infected cells, NS1-GFP expression could
be detected at the earliest by 8 hpi, suggesting a modest delay in
NS1-GFP expression.
NS1-GFP virus suppress IFN-β promoter activation.A well-characterized
function of IAV NS1 protein is the suppression of IFN-β pro-
moter induction via IRF-3 activation (14). We therefore exam-
ined whether this antagonist function of NS1 is intact in the NS1-
GFP virus. MDCK cells stably expressing ﬁreﬂy luciferase under
the control of the IFN-β promoter were infected with either WT
PR8 or NS1-GFP virus at a MOI of 1. An IAV carrying a de-
letion of NS1 (WSN ΔNS1) was used as a positive control. The
cell lysates were analyzed for ﬁreﬂy luciferase activity at 18 hpi as
an indirect quantiﬁcation of IFN-β promoter activity. The lucif-
erase activity in NS1-GFP virus–infected cells is similar to that in
PR8-infected cells, suggesting that the NS1-GFP virus is capable
of blocking IFN-β induction as efﬁciently as WT PR8 NS1 (Fig.
S1C). In contrast, WSN ΔNS1 virus, which lacks the ability to
block IFN-β induction, in infected cells showed nearly a 1,200-
fold activation of IFN-β promoter. These results show that the
NS1-GFP virus is competent in blocking the induction of IFN-β
promoter during IAV infection.
In Vivo Characterization of NS1-GFP Virus. NS1-GFP virus causes signiﬁcant
pathogenicity in mice. WT PR8 has been previously shown to cause
severe pathogenicity in mice (11, 15). To test whether the NS1-GFP
virus is comparable in disease induction to its parental virus, BALB/c
mice were infected intranasally with either NS1-GFP or WT PR8
virus at different doses, and body weight loss and survival were
measured (Fig. 2A andB and Fig. S2). In theWTPR8-infectedmice,
all mice infected with a dose 102 pfu or higher showed signiﬁcant
weight loss starting 2 dpi, and all mice succumbed to infection by
day 10 (Figs. S2A and 2A). In the NS1-GFP virus–infected mice, only
mice that received 104 pfu or higher showed signiﬁcant weight loss,
and all of them lost more than 25% body weight by day 9 and were
humanely killed (Figs. S2B and 2B). This indicates that NS1-GFP
virus is attenuated compared with PR8 virus. Based on the survival
data, we determined the LD50 value for NS1-GFP virus as 3,160 pfu,
∼100-fold higher than parental PR8 virus (31.60 pfu) (16). Despite
the attenuation of the NS1-GFP virus in vivo, it is still possible to use
a lethal dose of this virus in the murine model.
We then examined the viral titers in the lungs of infected mice
on day 3 and day 4 postinfection (Fig. 2C). The NS1-GFP virus
replicated efﬁciently in the lower respiratory tract of mice and
grew to nearly 5 × 106 pfu/mL, only 2-fold lower than WT PR8
virus. This slight reduction in replication is likely to account for
the increase in LD50.
Fig. 1. Generation of recombinant inﬂuenza virus carrying a GFP reporter.
(A) Schematic representation of NS segment of WT PR8 virus and NS1-GFP
virus. Splice acceptor site in NS was mutated to prevent mRNA splicing (SD-
splice donor site, SA- splice acceptor site). Common regions present in both
NS1 (light blue) and NEP (dark blue) are shown in red. NS1was fused to GFP
(green) via a GSGG linker, followed by PTV-1 2A autproteolytic cleavage site
(yellow) and NEP ORF (red-blue). (B) A549 cells were infected with recom-
binant PR8 virus carrying NS1-GFP. At 10 hpi, cells were ﬁxed and stained for
NP. NP staining is shown in red and NS1-GFP is shown in green. (C) Fluo-
rescent micrographs of NS1-GFP virus plaques taken at 20× magniﬁcation.
Fig. 2. In vivo characterization of NS1-GFP virus. (A and B) Comparison of
survival of PR8 and NS1-GFP virus–infected mice. BALB/c mice were in-
tranasally inoculated with indicated doses of PR8 or NS1-GFP virus. Survival
was monitored daily. (C) Viral titers in lungs of mice infected with WT PR8
virus and with NS1-GFP viruses. (D) Mice were intranasally inoculated with
either PR8 or NS1-GFP virus at indicated doses. Lungs were excised on day 4
postinfection, and ﬂuorescence from infected lungs was imaged using an
IVIS-200 imaging system (Xenogen). (E) Fluorescent micrographs of mice
lung cryosections (10× magniﬁcation).
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Whole-organ imaging of NS1-GFP virus replication. To longitudinally
follow the course of infection progression in the lungs of infected
mice, we imaged the NS1-GFP virus–infected mice using an
IVIS-200 series system (Xenogen). Five-wk-old BALB/c mice
were infected with WT PR8 (104 pfu) or NS1-GFP virus with
different doses (104, 106, and 107 pfu). WT PR8-infected mice
were used as controls for background ﬂuorescence. Unfortu-
nately, we found that background ﬂuorescence from skin and
tissues surrounding the rib cage precluded us from an in-depth
analysis of GFP expression in the lung of anesthetized mice
following virus infection. To overcome this, animals were killed
and their lungs were excised and imaged ex vivo on day 4 post-
infection (Fig. 2D). Upon viral infection, the level of ﬂuores-
cence from the lungs of NS1-GFP virus–infected mice was
signiﬁcantly higher than in WT PR8-infected mice (background),
indicating active replication of NS1-GFP virus in the lower re-
spiratory tract of infected mice (Fig. 2D). We observed a good
correlation between the amount of viral inoculum and the ﬂuo-
rescence signal from NS1-GFP virus–infected lungs, with ﬂuo-
rescence intensity increasing as the dose of the inoculum
increased. Furthermore, examination of cryosections of NS1-
GFP virus–infected lungs also showed infected cells expressing
NS1-GFP protein (Fig. 2E).
Kinetics of NS1-GFP Virus Infection in Mice. Previous studies have
shown that IAV infects both epithelial (CD45−) and hematopoi-
etic (CD45+) cells in vitro (8, 17–20). To better understand the
in vivo dynamics of IAV infection progression, and to identify the
speciﬁc cell types susceptible to IAV infection, BALB/c mice were
infected with NS1-GFP virus and then analyzed for GFP-positive
cells in lung homogenates using multicolor ﬂow cytometry. Rep-
resentative plots of the ﬂow-cytometric analysis of GFP in dif-
ferent cell types are shown in Figs. S3 and S4.
To ﬁnd the optimal viral dose that would allow us to follow the
kinetics of infection, mice were infected intranasally with NS1-
GFP virus at different doses (104, 106, and 107 pfu), and the
course of infection of nonhematopoietic cells (CD45−) was an-
alyzed at different times postinfection (Fig. 3A). Flow cytometry
analysis of lung cells showed an increase in the number of in-
fected cells as the NS1-GFP viral inoculum increased, correlating
well with the results from ex vivo imaging. In the 107 pfu-infected
mice, GFP-positive cells could be seen as early as 12 hpi, with
nearly 6% of CD45− cells being GFP positive, and these in-
fection levels remained sustained up to 72 hpi. At 96 hpi, the
number of GFP-positive cells decreased by nearly 3-fold. The 106
pfu-infected group showed a kinetic pattern of GFP-positive
cells with numbers peaking around 48–72 hpi at levels similar to
the 107 pfu-infected group. However, in the 104 pfu-infected
mice, despite showing severe pathogenicity, only 1% of CD45−
cells were GFP positive (2- to 3-fold higher than background
levels; Fig. 3A). Based on these data, the subsequent experiments
were performed with a dose of 106 pfu.
We next examined the expression of NS1-GFP in various sub-
sets of antigen presenting cells (APC) based on the surface ex-
pression patterns of CD11b and CD11c. Mice were intranasally
inoculated with 106 pfu of NS1-GFP virus, and the lung homo-
genates were analyzed for GFP presence in APCs using anti-
bodies speciﬁc for CD11b and CD11c surface markers at 12, 24,
48, 72, and 120 hpi (Fig. 3B). At 12 hpi, we observed a minimal
number of cells expressing NS1-GFP (<1%). However after 24
hpi, the number of GFP containing cells increased. At 48 hpi,
nearly 10% of the CD11b+ CD11c+ (conventional DCs) and
CD11b+ CD11c− (monocytes and neutrophils) cells were carrying
NS1-GFP. At this time only 2–3% of CD11b− CD11c+ (macro-
phages and dendritic cells) were GFP positive. After 96 hpi,
the numbers of GFP-positive cells started to decline, and only
CD11b+ CD11c+ cells carried signiﬁcantly higher levels of NS1-
GFP (∼6%). In addition, a signiﬁcant percentage of NK and
B cells were also GFP positive, suggesting that these cells are
targets of IAV infection (Fig. 4; No treatment). We also found
a minor portion of CD4 and CD8 cells carrying GFP (Fig. 4;
No treatment). Although macrophages, DC, and monocytes are
known to be susceptible to IAV infection in vitro, it is possible
that, in vivo, some of these cells are GFP positive due to uptake
of NS1-GFP virus–infected cells or from apoptotic cells (17–23).
Effects of Antiviral Treatments on NS1-GFP Infection Progression.
Although vaccination is the most effective means of protection
against lethal inﬂuenza virus infection, antiviral drugs such as
amantadine and oseltamivir are recommended for treatment of
inﬂuenza-like illnesses (4, 5). The mechanisms of action of these
drugs have been extensively studied in tissue culture. However, it
is unclear how these drugs modulate the progression of viral
infection in vivo. To understand how antiviral treatment affects
the kinetics of virus infection, mice were infected with 106 pfu of
NS1-GFP virus, and were treated daily with either amantadine
(40 mg/kg) or oseltamivir (50 mg/kg) starting 1 h after infection
(24). The effect of antiviral treatments was determined by ana-
lyzing NS1-GFP expression in different cells types using multi-
color ﬂow cytometry (Fig. 4). In mice that received no antiviral
drug, we observed a differential kinetic pattern of NS1-GFP ex-
pression in different cell types with the numbers of GFP-positive
cells peaking at 48–72 hpi. Oseltamivir treatment dramatically
reduced the infection rate in all of the examined cell types. We
were able to detect only modest levels of GFP positive cells in all
cell types (>2%). Interestingly, amantadine treatment was most
effective in blocking infection of NK and B cells, but was less
potent for other cell types (Fig. 4 F and G). Amantadine treat-
ment showed only a 50% reduction in infection of epithelial
(CD45−) and CD11b+ CD11c+ cells (Fig. 4 A and C). This drug
was effective in reducing the numbers of GFP-positive cells in
CD11b+ CD11c−, Gr1+ (inﬁltrating monocytes) and CD4 cells at
early times but not after 72 hpi (Fig. 4 D, E, and H). Taken to-
gether, these results show that oseltamivir treatment controls in-
fection progression in all cell types but that amantadine blocks
infection in a more cell type-speciﬁc manner.
To observe the global effects of oseltamivir treatment, ex vivo
analysis of whole lungs was performed (Fig. 5). Lungs from non-
infected mice were used as controls for background ﬂuorescence.
Analysis of mice lungs on day 2 postinfection showed a clear dif-
ference in the ﬂuorescence intensities between untreated mice and
oseltamivir-treatedmice (Fig. 5A). In both groups,most of theGFP
ﬂuorescence signal was concentrated in areas close to large con-
ducting airways. However, ﬂuorescence intensity was signiﬁcantly
lower in oseltamivir-treated mice than in untreated mice (3- to 5-
fold lower). Analysis of the untreated group on day 4 postinfection
showed GFP ﬂuorescence throughout the whole lung, demon-
strating the progression of infection into the lungs (Fig. 5B). How-
ever, oseltamivir treatment signiﬁcantly restricted the spread of
viral infection, as the GFP signal was detected only in localized
spots. Together, our data indicate that oseltamivir treatment
greatly reduces IAV infection in both epithelial and immune cells,
Fig. 3. Dynamics of inﬂuenza virus infection in lungs. (A) Kinetics of epi-
thelial cell infection. BALB/c mice were intranasally inoculated with NS1-GFP
virus at indicated doses, and lung homogenates were analyzed for GFP ex-
pression in nonhematopoietic cells (CD45−) using a BD LSR II ﬂow cytometer.
(B) Comparison of kinetics of hematopoietic and nonhematopoietic cell in-
fection in murine lungs. BALB/c mice were intranasally inoculated with 106
pfu NS1-GFP virus and analyzed for GFP expression in cells types differen-
tially expressing CD11b and CD11c. Each data point represents the average
from at least three mice.
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and that infection is restricted to small localized areas in the lung,
which may represent the initial sites of infection.
In Vivo and in Vitro Stability of GFP Expression by NS1-GFP Virus.
Although NS1-GFP virus replicated in mice, in the lung homoge-
nates, we observed a mixture of GFP-positive and GFP-negative
viruses, suggesting that some of the viruses may carry deletions in
the GFP transgene. To fully evaluate the in vivo stability of NS1-
GFP virus, mice were infected with 104 pfu of NS1-GFP virus, and
the percentages of GFP carrying virus in the lung homogenates
were assessed on days 2, 4, and 6 by scoring for GFP-positive or
GFP-negative plaques (Fig. S5A). The viral stocks used for murine
infection served as controls. The percentage of GFP-positive and
GFP-negative plaques varied among individual mice. We observed
that nearly 15% plaques were GFP negative in the day-2 and day-4
lung homogenates. However, in the lung homogenates from day 6
postinfection, nearly 30% of plaques were GFP negative, suggest-
ing increased loss of GFP or active replication of GFP deletion
viruses. To assess the kinetics of stability of GFP transgene in mice,
we compared GFP expression with viral nucleoprotein NP ex-
pression in nonimmune cells (CD45−) in mice infected with 106
pfu NS1-GFP virus. Unlike immune cells that can carry GFP by
phagocytosis of infected cells, nonimmune cells will carry GFP only
if they are infected. At 24 hpi, the percentage ofNP+ cells was twice
the percentage of GFP+ cells (Fig. S5B). At this time during in-
fection, the higher number NP+ cells is unlikely from the emer-
gence of GFP deletion virus but rather the early expression of NP
compared with NS1-GFP. During the course of infection, both
populations followed similar kinetic patterns. This correlates with
the plaque assay data showing that a majority of the virus pop-
ulation carry GFP (Fig. S5A).
We next examined the stability of NS1-GFP virus in vitro
during a multicycle replication in MDCK cells. MDCK cells were
infected with an MOI of 0.001, and the levels of GFP-positive
and GFP-negative viruses in the supernatants were examined by
plaque assay at various hpi (Fig. S5C). At 12 hpi, we observed
that nearly 5–10% of plaques were GFP negative. During mul-
ticycle replication, the number of GFP-negative viruses increased
from 25% to 45%, suggesting better growth of viruses carrying
deletions in GFP gene. Nevertheless, it is possible to generate
clonal populations of the NS1-GFP virus from single plaques
with more than 99% of GFP-positive viruses.
Discussion
In this study, we report the generation of a fully replication
competent inﬂuenza GFP reporter virus. The NS1-GFP virus
was attenuated for multicycle replication in MDCK cells and in
mice. Nevertheless, the NS1-GFP virus was still pathogenic in
mice. This phenotype allowed us to monitor the virus-infected
cells in vivo using a ﬂuorescent reporter gene during infection
with a lethal dose of inﬂuenza virus. Whole-organ imaging of
lungs of mice infected with NS1-GFP virus was consistent with
inﬂuenza virus infection, starting in the large conducting airways
and later spreading to the bronchioles and deeper areas in the
lungs. Although there was background ﬂuorescence in the large
conducting airways of noninfected mice, the ﬂuorescence in-
tensity in the large conducting airways of NS1-GFP virus–infected
Fig. 4. Oseltamivir and amantadine treatment signiﬁ-
cantly reduces NS1-GFP virus infection. Mice infected
with NS1-GFP virus either were left untreated or were
treated with oseltamivir (50 mg/kg) or amantadine (40
mg/kg), starting 1 h postinfection. Kinetics of infection
progression in different cell types were analyzed using
a BD LSR II ﬂow cytometer. (A–G) Kinetics of GFP ex-
pression in different cell types as indicated in treated
and untreated groups.
Fig. 5. Oseltamivir treatment restricts inﬂuenza virus infection to localized
areas. Ex vivo imaging of mice lungs on day 2 (A) and day 4 (B) postinfection.
BALB/c mice infected with NS1-GFP virus (106 pfu) either were left untreated
or were treated daily once with oseltamivir (50 mg/kg). Lungs of mice were
excised at indicated time and imaged using the IVIS-200 system (Xenogen).
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mice (ROI intensity, 203.50 ± 41.36) was nearly 2-fold higher
than in the noninfected mice (ROI intensity, 108.39 ± 14.56). We
also analyzed the in vivo dynamics of IAV infection by ﬂow
cytometry, and found that GFP is present in epithelial and he-
matopoietic cells including macrophages, monocyte, neutrophils,
respiratory dendritic cells, B, NK, CD4, and CD8 cells. Treatment
of mice with a NA inhibitor dramatically reduced virus spread-
ing to all cell types. However, treatment with an M2 inhibitor
effectively reduced infection of B and NK cells, but showed only
a modest effect in blocking infection of other cells, suggesting
that B and NK cells are more susceptible to the antiviral action of
amantadine. This differential susceptibility of cell populations
in vivo to the antiviral effects of two different inﬂuenza virus
drugs is likely to have implications for control of disease pro-
gression and the induction of immune responses.
In our NS1-GFP virus, the GFP reporter was introduced in the
middle of the NS segment to prevent any detrimental effect on
vRNA packaging signals present in the 3′ and 5′ ends. Previously,
Kittel et al. and Shinya et al. generated IAV carrying GFP by
replacing portions of NS or NA segment with GFP, respectively
(9, 10). However, these viruses were highly attenuated in cell
culture and mice. We have designed the NS1-GFP virus to ex-
press NS1-GFP and NEP as a single fusion protein (NS1-GFP-
2A-NEP), building on a strategy previously described by our
group (Fig. 1A) (11). NEP, which is essential for virus survival, is
separated from NS1-GFP protein by an autoproteolytic cleavage
reaction at 2A site.
In mice, the NS1-GFP virus caused signiﬁcant pathogenicity,
evidenced by signiﬁcant loss of body weight and by 100% le-
thality at doses ≥104 pfu (Fig. 2B and Fig. S2B). All of the mice
infected with 104 pfu of NS1-GFP virus reached the experimental
end point by day 9. Also, NS1-GFP virus replicated efﬁciently in
the lower respiratory tract of infected mice (Fig. 2C). In-
terestingly, we did notice nearly 5–30% of the GFP-negative
viruses in the murine lung homogenates, indicating that these
viruses are likely carrying deletions in the GFP (Fig. S5A). In our
multiple analyses of NS1-GFP virus stocks, we did not ﬁnd GFP-
negative plaques (limit, >10 pfu). The GFP-negative viruses may
arise due to selection pressure for viruses that contain deletions
or mutations at speciﬁc regions of the NS-GFP segment that
result in more ﬁt viruses in vivo. This is in contrast to nonseg-
mented, negative strand RNA viruses, which are known to stably
maintain GFP and other reporter genes inserted in their ge-
nomes after multiple passages (25). Nevertheless, as nearly 70%
of the virus population in the lungs of infected animals remained
GFP positive (day 6), we do not believe that our analysis has been
highly compromised by loss of GFP expression during infection.
Previous studies have shown that IAV preferentially replicate
in tracheal epithelial cells (8, 26). We analyzed the sites of initial
viral replication and the spreading from these sites in the murine
model by performing whole-organ imaging of NS1-GFP–infected
lungs. Ex vivo imaging of NS1-GFP virus–infected lungs revealed
that GFP ﬂuorescence signal was present mainly in areas closer
to large conducting airways during the initial stages of infection,
suggesting active replication of the NS1-GFP virus in this region
(Fig. 5A, No treatment). At later stages of infection, GFP signal
could be seen throughout the lung, indicating the spreading of
NS1-GFP virus deeper into the bronchioles and possible into the
alveoli spaces (Fig. 5B, No treatment; Fig. 2D). Treatment of
infected mice with oseltamivir effectively blocked viral spreading,
and NS1-GFP virus replication was observed in conﬁned regions
in the lungs. This is in agreement with the data from in vitro
studies that have demonstrated that oseltamivir restricts viral
spreading by blocking release of progeny virions from the infected
cells (reviewed in ref. 4). It is important to note that sites of IAV
replication and viral spreading in lungs are determined by several
viral/host factors, including the origin of virus (avian or human),
the hemagglutination receptor speciﬁcity, distribution of suscep-
tible cells, sialic acid receptor distributions, and temperature (27,
28). It has been proposed that these factors contribute to impaired
human-to-human transmission of highly pathogenic H5N1 virus
(29). Thus, recombinant inﬂuenza viruses expressing NS1-GFP
and derived from different strains might be used to address these
questions in different animal models.
Flow-cytometric analysis of infected lung homogenates re-
vealed the kinetics of IAV infection in different cell types. Mice
were infectedwith different doses (104, 106, or 107 pfu) ofNS1-GFP
virus, and the infection progression was followed in different cell
types. In the 107-pfu group, during the early stages of infection,
GFP expressionwas seenmostly in nonimmuneCD45− cells (12–24
hpi), indicating that these cells are the primary targets of IAV in-
fection, and only after 24 hpi was GFP expression detected in he-
matopoietic cells (Fig. 3). The percentage of GFP-positive epi-
thelial cells remained nearly 6% from 12 to 72 hpi. However, in
mice infectedwith 106 pfu, a kinetic pattern of infection progression
was observed. The number of infected cells in different cell types
remained at less than 1% at 12 hpi but increased over time,
reaching a peak at 48–72 hpi. We observed a distinct pattern of
susceptibility to infection by the NS1-GFP virus for different im-
mune cells in the following order: CD11b+ CD11c+ > Gr1+ ≥
CD11b+ CD11c− > CD11b− CD11c+. NS1-GFP was also present
in B, NK, CD4, and CD8 cells (Fig. 4). At 72 hpi, the number of
GFP-positive cells declined, probably due to clearance of infected
cells by the immune system and to migration of DCs to draining
lymph nodes. It is worthwhile noting that some of these cells ac-
tively take up foreign antigen and cell debris, so it is possible that
some these cells are not infected but, rather, carry the debris of
infected cells (30). Because of technical limitations, we were un-
able to differentiate between cells directly infected with NS1-GFP
virus and cells carrying infected-cell debris.
Several studies have shown that highly pathogenic viruses
such as the 1918 H1N1 virus and H5N1 viruses induce massive
inﬁltration of inﬂammatory cells (monocytes and neutrophils)
very early during infection, and that these viruses can replicate
efﬁciently in these cells (31–33). In addition, mice infected with
highly pathogenic H5N1 viruses show a decrease in numbers of
lymphocytes (34). Interestingly, in this study we found NS1-GFP
in hematopoietic cells, especially in DCs, monocytes (Gr1+),
neutrophils (CD11b+), B cells, and NK cells, which are critical for
controlling viral replication and development of effective adap-
tive immunity (35, 36). It is conceivable that highly pathogenic
inﬂuenza viruses may infect high levels of these cells and/or may
have preferential cellular tropism for immune cells and thereby
contribute to immune deregulation and disease aggravation. Use
of highly pathogenic inﬂuenza viruses expressing GFP might help
to elucidate these questions in the future.
Anti-inﬂuenza drugs such as amantadine and oseltamivir are
widely used for treatment of inﬂuenza-like illness (6, 7). Although
the mechanism of action for these drugs has been well character-
ized in vitro, it is still not clear how these drugs control infection
progression in vivo (4, 37–39). Here, we analyzed the effect of
antiviral treatment on NS1-GFP virus infection progression.
Oseltamivir treatment signiﬁcantly reduced NS1-GFP virus in-
fection in all cell types to less than 2% and restricted the NS1-GFP
virus replication to localized areas (Figs. 4 and 5). Amantadine was
more effective (3- to 4-fold) in preventing infection in B and NK
cells, but it reduced infection only to 50% in epithelial and
CD11b+ CD11c+ cells at the dose used (Fig. 4 A and C). In-
terestingly, amantadine treatment showed no effect in preventing
infection of monocytes (Gr1+) or neutrophils (CD11b+) at later
times of infection (Fig. 4 D and E). Because the ion channel ac-
tivity of M2s is required for acidiﬁcation of the inside of the virion
during endosomal-mediated viral entry, it is possible that differ-
ences in the endosomal physiology of different cell types are re-
sponsible for these effects. Further experimentation will be
required to investigate whether this is the case. Also, the levels of
inﬂammatory monocyte and neutrophil inﬁltration were different
in oseltamivir- and amantadine-treated mice. In oseltamivir-trea-
ted mice, the numbers of inﬁltrating cells were dramatically lower
than in amantadine-treatedmice, correlating well with the levels of
antigen present in the respiratory tract. This is in agreement with
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prior studies that have demonstrated that the viral load in the lungs
determines the levels of immune inﬁltration (33).
Here, we have demonstrated the generation of a unique, fully
replication-competent IAV carrying a GFP reporter gene (NS1-
GFP virus). The NS1-GFP virus efﬁciently replicates and causes
signiﬁcant pathogenicity in mice. By multicolor ﬂow-cytometric
analysis, we have analyzed cell types that are GFP positive during
infection. Our work provides the basis for future studies focused
on understanding the consequences of infection of different cell
populations. In addition, the generation of different inﬂuenza
virus strains carrying a GFP reporter will allow further and more
speciﬁc investigation of strain speciﬁc effects in pathogenesis,
tissue tropism, and replication kinetics in different hosts in vivo.
Finally, the same strategy could be adapted to generate recombi-
nant inﬂuenza viruses carrying foreign genes in their NS seg-
ments, which can be used as a vaccines or gene therapy candidates.
Materials and Methods
Construction of NS-GFP Segment. TheNS segment (A/PuertoRico/8/34) carrying
GFPwasgeneratedbyoverlappingfusionPCRusingstandardmolecularbiology
techniques. Brieﬂy, the NS1 ORF without the stop codon was fused to the N-
terminal of a codon-optimizedmaxGFP (Amaxa) via a GSGG linker region (NS1-
GFP).ThemaxGFPwasfollowedbyashortGSGlinker,a19-aa2Aautoproteolytic
site (ATNFSLLKQAGDVEENPG⇓P) (12) derived from porcine teschovirus–1 and
by the NEP ORF (Fig. 1A). Also, silent mutations in the endogenous splice ac-
ceptor site in the NS1 ORF were introduced to prevent splicing (11). The engi-
neered NS-GFP segment was cloned in the pDZ IAV rescue plasmid (13).
Murine Experiments. All animal procedures performed in this study were
conducted in accordance with Institutional Animal Care and Use Committee
(IACUC) guidelines, and were approved by the IACUC of Mount Sinai School
of Medicine.
Body weight loss and survival. Female BALB/c mice (5–6 wk of age) were
anesthetized with ketamine–xylaxine and intranasally infected with the
indicated virus dose diluted in 50 μL PBS. Body weight and survival were
measured daily. Mice showing more than 25% of body weight loss were
considered to have reached the experimental end point and were hu-
manely killed.
Antiviral treatments. Mice were treated with either 50 mg/kg oseltamivir
phosphate in PBS (Roche) or 40 mg/kg amantadine hydrochloride in H2O
(Sigma), administered by oral gavage (24). The treatments were started 1 h
postinfection and were given once daily until the end of the experiment.
Flow Cytometry. Single-cell suspensions of mice lung were prepared using
collagenase/DNase treatment. Cells were stained with commercial antibodies
and analyzed using a BD LSR II ﬂow cytometer.
More detailed descriptions of the experimental procedure are included in
SI Materials and Methods.
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SI Materials and Methods
Cell Lines.Human embryonic kidney (293T) cells were maintained
in DMEM supplemented with 10% FBS and 1,000 units/mL pen-
icillin/streptomycin. MDCK cells were maintained in MEM sup-
plemented with 10% FBS and penicillin/streptomycin. Reagents
for cell culture were purchased from Gibco Life Technologies.
Plaque Assay. MDCK cells were seeded in six-well plates, 1 d
before infection, at a dilution of 106 cells/well. The next day, the
cells were washed once with 2 mL PBS and incubated with virus
diluted in 200 μL PBS containing 0.3% bovine albumin (BA) and
1,000 u/mL penicillin/streptomycin (PBS/BA; MP Biochemicals)
for 1 h at 37 °C with frequent shaking. After incubation, the virus
inoculum was removed and overlayed with MEM containing
a 0.6% oxoid agar and 1 μg/mL L-(tosylamido-2-phenyl) ethyl
chloromethyl ketone (TPCK)-treated trypsin (Sigma). The pla-
ques were visualized by staining with Crystal Violet.
Rescue of NS1-GFP Virus. NS1-GFP virus (A/Puerto Rico/8/34 back-
ground) was rescued using standard reverse genetics techniques (1).
Brieﬂy, 0.5 μg of each of eight pDZ plasmids representing the eight
segments of the IAV genome were transfected into 293T cells using
Lipofectamine 2000 (Invitrogen). After 24 h, the 293T cells were
resuspended in themedium, and 100 μLof themix was injected into
8-d-old eggs. The NS1-GFP virus was harvested from the allantoic
ﬂuid at 48 hpi. The successful rescue of virus were conﬁrmed by
performing hemagglutination assay with chicken red blood cells.
After plaque puriﬁcation, NS1-GFP virus was ampliﬁed in 9-d-old
embryonated eggs. The sequence of the NS-GFP segment in the
NS1-GFP virus was conﬁrmed by RT-PCR and sequencing. Titers
of viral stocks were determined by plaque assay in MDCK cells.
Single-Cycle and Multicycle Growth Curve.MDCK cells were seeded
at a dilution of 106 cells per well in six-well plates, 1 d before in-
fection. The cells were washed with 2 mL PBS and incubated with
103 pfu virus (single-cycle) or 106 pfu (multicycle) virus diluted in
200 μL PBS/BA. After incubation for 1 h at 37 °C with frequent
shaking, the virus inoculum was removed and 3 mL MEM con-
taining 0.3% BA and 1 μg/mL TPCK-treated trypsin were added.
At indicated times, nearly 300 μL of supernatant was removed for
virus titration and was replenished with same amount of fresh
medium. Viral titers were determined by plaque assay.
Immunostaining. A549 cells were infected with NS1-GFP virus at
a MOI of 1. At 10 hpi, the cells were washed with PBS and ﬁxed in
1 mL 4% formaldehyde (methanol-free) for 10 min. After per-
meabilization with 0.5% Triton X-100 in PBS, the cells were
stained in PBS containing 2% BSA with a rabbit polyclonal anti-
NP antibody. The cells were washed twice in PBS and stained with
antirabbit secondary antibody conjugated to Alexa-588 (Invi-
trogen). Images were acquired on an Olympus XI-70 microscope
at 20× using Q-Capture software.
Western Blot Analysis.MDCK cells in six-well plates were infected
at a MOI of 1, and cells were lysed using 1% Triton X-100 lysis
buffer (50 mM Tris-HCl, pH 7.5,150 mMNaCl, 5 mMEDTA,1%
Triton X-100, and protease inhibitors) at the indicated times
postinfection. The protein samples were subjected to SDS/PAGE
and transferred to a polyvinylidene diﬂuoride membrane. WT
NS1 and NS1-GFP levels were assessed by immunoblotting with a
rabbit polyclonal anti-NS1 antibody raised against the N-terminal
1–73 amino acids of NS1 from A/Swine/Texas/4199–2/98 (dilu-
tion 1:3,000) followed by an antirabbit secondary antibody (dilu-
tion 1:10,000) conjugated to HRP (GE Healthcare Life Sciences).
IFN-β Promoter Induction Assay. MDCK cells stably expressing
ﬁreﬂy luciferase under the control of the human IFN-β (IFN-β)
promoter were infected with a MOI of 1. At 18 hpi, the cells
were washed with 2 mL PBS and lysed in 200 μL cell culture lysis
reagent (Promega). The luciferase activity in 100 μL of cell lysate
was measured with a ﬁreﬂy luciferase assay kit (Promega). Each
experiment was performed in triplicate and repeated at least
three times.
Murine Experiments.All animal procedures performed in this study
were conducted in accordance with Institutional Animal Care and
Use Committee (IACUC) guidelines, and have been approved by
the IACUC of Mount Sinai School of Medicine.
Determination of LD50 . Female BALB/c mice (6 wk of age) were
anesthetized with ketamine–xylazine and intranasally infected
with PR8 or NS1-GFP virus in 50 μL at indicated doses (n = 5
per group). The mice were monitored daily for survival and body
weight loss over a period of 14 d. Mice showing more than 25%
of body weight loss were considered to have reached the ex-
perimental end point and were humanely euthanized. LD50
values were calculated by the method of Reed and Muench (2).
Lung titers. Lungs of infected mice were excised on days 3 and 4
postinfection and homogenized in 1 mL PBS/BA, using a me-
chanical homogenizer. The viral titers in the homogenates were
quantiﬁed by plaque assay on MDCK cells. Each data point re-
presents the average titer from three mice.
Lung cryosections. After surface cleaning with PBS, murine lungs
were placed in OCT media and slowly frozen in −80 °C. Lung
sections 5 μm in thickness were cut using a cryostat and placed
on a glass slide. The sections were ﬁxed in 200 μL PBS con-
taining 4% formaldehyde for 10 min and washed twice with PBS.
The nuclei were stained with DAPI. Images were acquired on an
Olympus XI-70 microscope at 10× using Q-Capture software.
Ex vivo imaging of lungs. The lungs of infected mice were excised at
the indicated times postinfection. After cleaning with PBS, the
lungs were placed on a glass plate and imaged using the IVIS-200
series imaging system (Xenogen) ﬁtted with GFP excitation/
emission ﬁlters at 4-s exposure time.
Flow Cytometry. Single-cell preparation. Single-cell suspensions of
mice lung were prepared using collagenase/DNase treatment.
Brieﬂy, excised whole lungs were minced in 10 mL DMEM
containing 10 mM Hepes, 5% FBS, 100 units/mL Type IV
Collagenase (Worthington), and 100 μg/mL DNase I (Roche),
and incubated at 37 °C for 30 min. Tissue pieces were meshed
through a 70-μm cell strainer. Cells were washed once with
HBSS containing 10 mM Hepes buffer, 2% FBS, and 2 mM
EDTA, followed by ﬁltration using a 40-μm cell strainer. Red
blood cells in the preparation were lysed using 1 mL ACK lysis
buffer (Lonza). Cells were pelleted and washed once with HBSS.
Staining and analysis cell surface markers.Approximately 1 × 106 cells
were stained in 100 μL HBSS (10 mM Hepes, 2% FBS, 2 mM
EDTA) using commercially available antibodies in the presence
of Fc receptor blocking antibody (2.4G2) for 30 min on ice.
Monoclonal antibodies conjugated to different ﬂuorochromes
(PerCP-Cy5.5, APC, APC-CY7, Paciﬁc blue, PE, PE-Cy7) were
purchased from BD Biosciences and Ebioscience. Antibody
clones used in cell surface staining were Fc block (2.4G2), CD45
(30-F11), CD11c (HL3), CD11b (M1/70), CD4 (GK1.5), CD8a
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(53-6.7), Gr1 (RB6-8c5), B220 (RA3-6B2), Pan NK (DX5), and
MHCII (M5/11.15.2). After 30 min incubation, the cells were
washed twice with HBSS buffer and used directly for ﬂow cy-
tometry or for intracellular staining.
Intracellular staining.After staining for cell surfacemarkers, the cells
were ﬁxed and permeabilized in 100 μL BD Cytoﬁx/Cytoperm
solution for 30 min. The cells were washed twice with BD Perm/
Wash buffer and stained with anti-NP monoclonal antibody
conjugated with Alexa-532 ﬂuorphore and anti-GFP polyclonal
antibody conjugated with Alexa-488 ﬂuorophore (Evorgen). Af-
ter incubation for 30 min on ice, the cells were washed three
times with BD Perm/Wash buffer and once with HBSS/2%
FBS buffer.
Flow cytometry was performed on a BD LSR II ﬂow cytometer
using FACSDiva software (BD Biosciences). The data were
analyzed using FlowJo Software (Tree Star).
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Fig. S1. In vitro characterization of NS1-GFP virus. (A) Single-cycle (MOI = 1) and multicyle (MOI = 0.001) growth kinetics in MDCK cells. (B) Western blot
analysis of NS1 and NS1-GFP expression in MDCK cells. (C) Analysis of IFN-β promoter activation by NS1-GFP virus.
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Fig. S2. In vivo characterization of NS1-GFP virus. Comparison of pathogenicity of PR8 and NS1-GFP viruses in mice. Five-wk-old female BALB/c mice were
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Fig. S3. Analysis of GFP expression in different APCs differentially expressing CD11b and CD11c. (Upper) Representative analysis of cells from control
(noninfected) mice. (Lower) Representative analysis of cells from NS1-GFP virus–infected mice lungs at 48 hpi.
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Fig. S4. Analysis of GFP expression in CD4, CD8, B, and NK cells based on cellular markers. (Upper) Representative analysis of cells from control (noninfected)
mice. (Lower) Representative analysis of cells from NS1-GFP virus–infected mice lungs at 48 hpi.
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Fig. S5. Characterization of in vivo and in vitro stability of NS1-GFP virus. (A) Stability of NS1-GFP virus in vivo. Mice were infected with 104 pfu of NS1-GFP
virus. Percentage of NS1-GFP carrying viruses in lung homogenates were analyzed by standard plaque assay, followed by scoring for GFP-positive or GFP-
negative plaques. Each data point represents the average from at least three mice. (B) Kinetics of NP and GFP expression in CD45− cells from NS1-GFP virus–
infected mice. Female BALB/c mice were infected with NS1-GFP virus at a dose of 106 pfu. Levels of NP and GFP expression in CD45− cells were analyzed using
anti-NP– and anti-GFP–speciﬁc antibodies in a BD LSR II ﬂow cytometer. Each data point represents average from at least three mice. (C) Stability of NS1-GFP
virus in vitro. MDCK cells were infected with an MOI of 0.001. Supernantant was collected at indicated hpi and scored for levels of GFP-positive and GFP-
negative plaques.
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